

UK NEQAS FOR H&I SCHEME 2A - CYTOTOXIC CROSSMATCHING

PBL/T-CELL CROSSMATCHING RESULTS OF SAMPLE 2A09/2014 PC

DESPATCHED ON 16TH SEPTEMBER 2014

HLA PHENOTYPE OF BLOOD DONOR: HLA-A1, A23; B44, B37; Cw4, Cw6; DR4, DR7; DQ2, DQ8

Summary of Results					Summary of Results			
Total tested	27	26	27	27	22	21	22	22
Positive	1	0	1	0	1	0	0	0
Negative	26	26	26	27	21	21	22	22
Not Tested / Equivocal	1	2	1	1	1	2	1	1
% Positive	3.7%	0.0%	3.7%	0.0%	4.5%	0.0%	0.0%	0.0%
% Negative	96.3%	100.0%	96.3%	100.0%	95.5%	100.0%	100.0%	100.0%
Consensus	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative
HLA Antibody (Defined By CDC)	DQ3	A32,B44,DR7	Bw6	B7,DR2				

Lab No.	Without DTT				With DTT (Not assessed)				Comments
	Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	
112	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
116	Positive	Negative	Positive	Negative	Positive	Negative	Negative	Negative	
119	Negative	Equivocal	Negative	Negative	Negative	Equivocal	Negative	Negative	
120	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
128	Negative	Negative	Negative	Negative					
139	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
143	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
147	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
149	Negative	Negative	Negative	Negative					
154	Negative	Negative	Negative	Negative					
159	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
174	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
181	Negative	Negative	Negative	Negative					
189	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
190	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
193	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
194	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
195	NT	NT	NT	NT	NT	NT	NT	NT	Late delivery of the samples - No cells
197	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
209	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
216	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
229	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
232	Negative	Negative	Negative	Negative					
238	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
260	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
262	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
297	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
315	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	

UK NEQAS FOR H&I SCHEME 2A - CYTOTOXIC CROSSMATCHING

PBL/T-CELL CROSSMATCHING RESULTS OF SAMPLE 2A09/2014 PC

DESPATCHED ON 16TH SEPTEMBER 2014

Lab No.	Without DTT				With DTT (Not assessed)				Date received	Date tested	Cells used		Immunobeaded cells used?	Cell viability %		Complement manufacturer	Incubation Times		Visualisation of dead cells
	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength			PBL	T-cells		PBL	T-cells		pre C'	post C'	
112	1	1	1	1	1	1	1	1	23-Sep	24-Sep	Yes		No	90		Cedarlane	30	60	Stain Fix
116	6	1	2	1	2	1	1	1	17-Sep	18-Sep		Yes	No		93	Cedarlane	20	60	EB/AO
119	1	2	1	1	1	2	1	1	18-Sep	18-Sep	Yes		No	95		BioRad	30	60	Eosin
120	1	1	1	1	1	1	1	1	17-Sep	18-Sep		Yes	Yes		100	Servibio	30	60	EB/AO
128	1	1	1	1					17-Sep	19-Sep	Yes		No	95		One Lambda	45	90	Stain Fix
139	1	1	1	1	1	1	1	1	18-Sep	19-Sep	Yes	Yes	Yes	90	90	Cedarlane	30	60	Eosin
143	1	1	1	1	1	1	1	1	18-Sep	19-Sep		Yes	Yes		98	Cedarlane	30	60	Eosin
147	1	1	1	1	1	1	1	1	17-Sep	17-Sep		Yes	Yes		100	In-House	30	60	Fluoroquench
149									17-Sep	18-Sep	Yes			90			60	60	Eosin
154	1	1	1	1					17-Sep	18-Sep		Yes	No	95		Cedarlane	30	60	Eosin
159	1	1	1	1	1	1	1	1	17-Sep	18-Sep		Yes	Yes		90	In-House	30	60	Fluoroquench
174									22-Sep	22-Sep	Yes		No	96		One Lambda	60	120	Eosin
181	1	1	1	1					17-Sep	17-Sep	Yes			100		Cedarlane	30	45	EB
189	1	1	1	1	1	1	1	1	18-Sep	18-Sep	Yes		No	90		BioRad	40	40	EB/AO
190	1%	1%	1%	1%	1%	1%	1%	1%	17-Sep	17-Sep		Yes	Yes		99	Cedarlane	30	60	Fluoroquench
193	1	1	1	1	1	1	1	1	17-Sep	17-Sep		Yes	No		99	Cedarlane	30	60	Stain Fix
194	1	1	1	1	1	1	1	1	17-Sep	18-Sep		Yes	Yes		100	In-House	30	45	Fluoroquench
195	NT	NT	NT	NT	NT	NT	NT	NT	01-Oct	NT	NT	NT	NT	0	0	NT	NT	NT	NT
197									17-Sep	18-Sep		Yes	Yes		90	One Lambda	30	60	Fluoroquench
209									17-Sep	18-Sep	Yes		No	90		Ingen	30	60	Fluoroquench
216	1	1	1	1	1	1	1	1	18-Sep	19-Sep	Yes		No	95		BioRad	30	60	PI
229	100	100	100	100	100	100	100	100	18-Sep	18-Sep	Yes		No	90		Cedarlane	30	60	EB/AO
232									18-Sep	19-Sep			No	80		Biotest	45	60	EB/AO
238	1	1	1	1	1	1	1	1	17-Sep	18-Sep		Yes	Yes		95	Invitrogen	45	90	Fluoroquench
260									18-Sep	18-Sep		Yes	Yes		90	Innotrain	30	60	EB/AO
262	1	1	1	1	1	1	1	1	17-Sep	17-Sep	Yes	Yes	Yes	100	100	Invitrogen	30	60	Eosin
297	1	1	1	1	1	1	1	1	17-Sep	18-Sep	Yes	Yes	Yes	90	90	Cedarlane	30	60	Fluoroquench
315	1	1	1	1	1	1	1	1	17-Sep	18-Sep		Yes	Yes		80	Servibio	30	50	Fluoroquench

© Copyright Notice: Reports are confidential, and no data may be published without permission from UK NEQAS for H&I

EB - ethidium bromide
AO - acridine orange
PI - propidium iodide
Hb - haemoglobin
CFDA - carboxy-fluorescein diacetate

UK NEQAS FOR H&I SCHEME 2A - CYTOTOXIC CROSSMATCHING

B-CELL CROSSMATCHING RESULTS OF SAMPLE 2A09/2014 PC

DESPATCHED ON 16TH SEPTEMBER 2014

HLA PHENOTYPE OF BLOOD DONOR: HLA-A1, A23; B44, B37; Cw4, Cw6; DR4, DR7; DQ2, DQ8

Summary of Results					Summary of Results				
Total tested	14	14	14	13	13	12	13	12	
Positive	5	10	0	0	3	9	0	2	
Negative	9	4	14	13	10	3	13	10	
Not Tested / Equivocal	2	2	2	2	2	2	2	2	
% Positive	35.7%	71.4%	0.0%	0.0%	23.1%	75.0%	0.0%	16.7%	
% Negative	64.3%	28.6%	100.0%	100.0%	76.9%	25.0%	100.0%	83.3%	
Consensus	Not Assessed	Not Assessed	Negative	Negative	Negative	Positive	Negative	Negative	
HLA Antibody (Defined By CDC)	DQ3	A32,B44,DR7	Bw6	B7,DR2					

Lab No.	Without DTT				With DTT (Not assessed)				Comments
	Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	
120	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
139	Positive	Positive	Negative	Negative	Positive	Positive	Negative	Negative	
147	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative	
154	Uninterpretable	Uninterpretable	Uninterpretable	Uninterpretable					Not enough B-cell recovered
159	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative	
181	Negative	Negative	Negative	Negative					
190	Positive	Positive	Negative	Negative	Negative	Positive	Negative	Negative	
193	NT	NT	NT	NT	NT	NT	NT	NT	
194	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Positive	
195	NT	NT	NT	NT	NT	NT	NT	NT	Late delivery of the samples - No cells
197	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Positive	
209	Positive	Positive	Negative	Negative	Negative	Positive	Negative	Negative	
238	Positive	Positive	Negative	Uninterpretable	Positive	Positive	Negative	Uninterpretable	High mortality of B-cells
260	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
262	Positive	Positive	Negative	Negative	Positive	Positive	Negative	Negative	
297	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative	
315	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	

UK NEQAS FOR H&I SCHEME 2A - CYTOTOXIC CROSSMATCHING

B-CELL CROSSMATCHING RESULTS OF SAMPLE 2A09/2014 PC

DESPATCHED ON 16TH SEPTEMBER 2014

Lab No.	Without DTT				With DTT (Not assessed)				Date received	Date tested	Immunobeaded cells used	B-cell viability %	Complement manufacturer	Incubation Times		Visualisation of dead cells
	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength						pre C'	post C'	
120	1	1	1	1	1	1	1	1	17-Sep	18-Sep	Yes	60	Servibio	30	60	EB/AO
139	4	8	1	1	4	8	1	1	18-Sep	19-Sep	Yes	90	Cedarlane	30	60	Eosin
147	1	6	1	1	1	4	1	1	17-Sep	17-Sep	Yes	100	In-House	30	60	Fluoroquench
154									17-Sep	18-Sep	No	20	Cedarlane			Stain Fix
159	1	8	1	1	1	6	1	1	17-Sep	18-Sep	Yes	90	In-House	30	60	Fluoroquench
181	1	2	1	1					17-Sep	17-Sep	Yes	100	Cedarlane	30	45	EB
190	50%	60%	15%	10%	20%	50%	15%	15%	17-Sep	17-Sep	Yes	90	Cedarlane	30	60	Fluoroquench
193	NT	NT	NT	NT	NT	NT	NT	NT	17-Sep	17-Sep	Yes	98	Cedarlane	30	60	Hb/PI
194	1	6	1	1	1	4	1	1	17-Sep	18-Sep	Yes	100	In-House	30	45	Fluoroquench
195	NT	NT	NT	NT	NT	NT	NT	NT	01-Oct	NT	NT	0	NT	NT	NT	NT
197									17-Sep	18-Sep	Yes	90	One Lambda	30	60	Fluoroquench
209	2	4				2			17-Sep	18-Sep	Yes	85	Ingen	30	60	Fluoroquench
238	4	4	1	0	2	4	1	0	17-Mar	18-Sep	Yes	70	Invitrogen	45	90	Fluoroquench
260									18-Sep	18-Sep	Yes	75	Innotrain	30	60	EB/AO
262	8	8	1	1	8	8	1	1	17-Sep	17-Sep	Yes	100	Invitrogen	60	90	Eosin
297	2	6	1	1	2	6	1	1	17-Sep	18-Sep	Yes	90	Cedarlane	30	60	Fluoroquench
315	1	1	1	1	1	1	1	1	17-Sep	18-Sep	Yes	80	Servibio	30	50	Fluoroquench

© Copyright Notice: Reports are confidential, and no data may be published without permission from UK NEQAS for H&I

EB - ethidium bromide
AO - acridine orange
PI - propidium iodide
Hb - haemoglobin
CFDA - carboxy-fluorescein diacetate